Reata Pharmaceuticals, Inc. (NASDAQ:RETA) posted its earnings results on Monday. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.11), Briefing.com reports. The business had revenue of $12.60 million during the quarter, compared to the consensus estimate of $12.54 million. The business’s revenue for the quarter was up .0% on a year-over-year basis.
Reata Pharmaceuticals (NASDAQ RETA) traded down $2.37 during trading on Tuesday, hitting $25.19. The company had a trading volume of 510,300 shares, compared to its average volume of 116,495. Reata Pharmaceuticals has a 12-month low of $18.51 and a 12-month high of $41.60. The company has a debt-to-equity ratio of -0.09, a current ratio of 1.34 and a quick ratio of 1.34.
COPYRIGHT VIOLATION NOTICE: “Reata Pharmaceuticals, Inc. (RETA) Issues Quarterly Earnings Results” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/11/14/reata-pharmaceuticals-inc-reta-issues-quarterly-earnings-results.html.
Several equities analysts have issued reports on the company. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $61.00 target price (up previously from $55.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, July 26th. Robert W. Baird restated an “outperform” rating and set a $47.00 price target (up previously from $43.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, July 25th. ValuEngine upgraded Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 26th. Jefferies Group LLC restated a “buy” rating and set a $44.00 price target on shares of Reata Pharmaceuticals in a research note on Friday, October 6th. Finally, Piper Jaffray Companies boosted their price target on Reata Pharmaceuticals from $53.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, July 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $54.71.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.